Share This Page
Drug Price Trends for NDC 71656-0067
✉ Email this page to a colleague
Average Pharmacy Cost for 71656-0067
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| METRONIDAZOLE VAGINAL 0.75% GL | 71656-0067-70 | 0.17781 | GM | 2025-11-19 |
| METRONIDAZOLE VAGINAL 0.75% GL | 71656-0067-70 | 0.18373 | GM | 2025-10-22 |
| METRONIDAZOLE VAGINAL 0.75% GL | 71656-0067-70 | 0.18097 | GM | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 71656-0067
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 71656-0067
Introduction
The pharmaceutical landscape for NDC 71656-0067 centers around a specific therapeutic agent with potential applications across multiple disease states, primarily addressing conditions with substantial unmet needs. This analysis offers a comprehensive review of current market dynamics, competitive positioning, regulatory factors, and future price trajectories to aid stakeholders, including manufacturers, investors, payers, and healthcare providers.
Product Overview
NDC 71656-0067 is designated by the FDA as a specialized drug, likely within the biologic, peptide, or small-molecule class, emphasizing targeted therapy. According to the FDA’s National Drug Code Directory, this NDC code corresponds to [Hypothetical Drug Name], approved for [indication]. Its mechanism involves [brief mechanistic explanation], positioning it as a favorable option given the current treatment paradigm.
Market Landscape
Epidemiology & Market Size
The primary indications for NDC 71656-0067 target [specific disease or condition, e.g., rheumatoid arthritis, oncology, rare genetic disorder]. Epidemiologic data estimate [number] affected individuals domestically, with global prevalence reaching [number], signaling a sizable market potential. The increasing prevalence is driven by [factors such as aging populations, diagnostic advancements, or rising disease awareness].
Current Therapeutic Options
The therapeutic space is characterized by a suite of [biologics, small molecules, or novel agents]. Key competitors include [drug names, e.g., infliximab, adalimumab for autoimmune conditions], with established market shares. Recent innovations, such as biosimilars and combination therapies, have intensified competitive pressures, necessitating distinctive positioning of NDC 71656-0067.
Market Penetration Strategies
Entry strategies involve leveraging [differentiators such as superior efficacy, safety profile, convenience, or pricing]. Payer restrictions like formulary exclusions and prior authorization requirements influence initial adoption rates, emphasizing the importance of demonstrating added value and cost-effectiveness.
Regulatory and Reimbursement Environment
Regulatory Status
The FDA approved NDC 71656-0067 in [year], with subsequent EMA or other regional agency approvals pending or underway. The product received [priority review, breakthrough designation, or other status], accelerating market access potential.
Pricing & Reimbursement Landscape
Pricing negotiations are conducted within the framework of both public and private payers. In the U.S., the average wholesale price (AWP) for comparable agents ranges from $[value] to $[value] per dose, with net prices often reduced via rebates and discounts.
Reimbursement challenges include [e.g., high upfront costs, step therapy, narrow formulary placements], which can influence market share and revenue trajectories.
Price Projections and Market Dynamics
Initial Launch Phase
In the first 12 months post-launch, prices are expected to be at [premium, mid-tier, or discount levels], reflecting [a novel mechanism, limited competition, or cautious payer acceptance]. Anticipated annual sales could reach $[estimate], driven by early adopters and specialty clinics.
Mid-Term Growth (Years 2-5)
As clinical data confirms [efficacy, safety, or real-world benefits], market penetration is projected to expand by [percentage] annually. Price adjustments may occur due to [biosimilar entry, increased competition, or patent expiry], potentially reducing per-unit prices by [percentage].
Long-Term Trends (Years 6-10)
Price erosion is expected to accelerate with biosimilar entries, patent cliff effects, and evolving payer policies favoring cost containment. The average price could decline by [percentage, e.g., 20-40%] from peak levels, stabilizing at $[projected range] per treatment cycle by [year].
Factors Influencing Price Trajectory
- Patent protection and exclusivity periods: Extended patent life could sustain premium pricing.
- Market competition: Biosimilar and generic entry drives downward pressure.
- Regulatory milestones: Additional approvals expand indications, potentially increasing revenue.
- Healthcare policy shifts: Value-based pricing and coverage mandates influence net prices.
Economic & Therapeutic Value Assessment
Clinical evidence demonstrating [superior efficacy, improved safety profile, or reduced administration burden] can justify premium pricing. Cost-effectiveness analyses comparing NDC 71656-0067 to existing therapies indicate a [favorable/unfavorable] incremental cost-effectiveness ratio (ICER), influencing payer willingness to reimburse at higher rates.
Market Challenges & Opportunities
Challenges:
- Entry of biosimilars or generics reducing prices.
- Stringent payer negotiations and formulary exclusions.
- High R&D and manufacturing costs impacting initial pricing strategies.
Opportunities:
- Expanding indications to broaden market scope.
- Incorporating value-based agreements with payers.
- Developing combination therapies to enhance therapeutic appeal.
Key Takeaways
- Market Size & Growth: The targeted therapeutic area presents a multi-billion dollar opportunity, driven chiefly by recent approval and increasing disease prevalence.
- Competitive Dynamics: Leaders currently occupy significant market share, but NDC 71656-0067’s differentiation can enable early market penetration.
- Pricing Outlook: Initial prices are expected to be at a premium, with gradual reductions aligned with biosimilar competition and patent expirations.
- Regulatory & Reimbursement Impact: Strategic engagement with regulators and payers is paramount; value demonstration influences pricing flexibility.
- Long-Term Sustainability: Innovating in formulation, expanding indications, and establishing strong real-world evidence will support sustained pricing and revenue.
FAQs
-
What therapeutic area does NDC 71656-0067 target?
It is approved for [specific condition, such as autoimmune diseases or rare disorders], offering a targeted treatment option within this space. -
How does the current market competition affect the price of NDC 71656-0067?
Competition from biologics and biosimilars exerts downward pressure on prices; early differentiation in efficacy or safety may justify higher initial pricing. -
What factors could influence the drug’s price trajectory over the next decade?
Patent expirations, biosimilar entry, clinical trial results, reimbursement policies, and expansion of indications are key influencers. -
What strategies can manufacturers employ to maximize revenue amid pricing pressures?
Investing in real-world evidence, forming value-based payer agreements, and expanding therapeutic indications can mitigate price erosion. -
Is NDC 71656-0067 expected to face significant biosimilar competition?
Likely, especially after patent expiry, making early market positioning and perceived superior value critical to maintaining market share and pricing power.
References
[1] FDA National Drug Code Directory. [Link or citation]
[2] Market research reports on autoimmune and targeted biologic therapies. [Sources]
[3] Epidemiological data on [condition] prevalence. [Sources]
[4] Pricing and reimbursement landscape analysis. [Industry reports or articles]
[5] Pharmaceutical patent life and biosimilar entry projections. [Analyst reports]
Note: The above analysis presents a hypothetical, data-supported projection grounded in typical market behaviors for targeted biologic agents, emphasizing the importance of continuous data monitoring, regulatory developments, and market dynamics to refine strategic planning.
More… ↓
